CTLA4 and neoplasm: The complex tumour immune microenvironment of the LHIC is also one of the main causes of the heterogeneity of the treatment response to immune checkpoint blockers such as PD-1 and CTLA-4 blockade in LHIC patients with the same TNM stage (Prieto et al., 2015).